Safety and Efficacy Study of TG-873870 (Nemonoxacin) in Diabetic Foot Infections

Summary

Safety and Efficacy Study of TG-873870 (Nemonoxacin) in Diabetic Foot Infections

Conditions

• Diabetic Foot Infections

Interventions

DRUG

TG-873870 (Nemonoxacin)

750 mg

Sponsors & Collaborators

• TaiGen Biotechnology Co., Ltd.

  lead INDUSTRY

Principal Investigators

• Kuang-Chung Shih, M.D. · Tri-Service General Hospital, Taipei, Taiwan

• Jawl-Shan Hwang, M.D. · Cheng-Gung Memorial Hospital - LinKou, Taiwan

• Te-Lin Hsia, M.D. · Cardinal Tien Hospital (CTH), Taiwan

• Jung-Fu Chen, M.D. · Chang Gung Memorial Hospital- Kaoshiung, Taiwan

• Chien-Wen Chou, M.D. · Chi-Mei Medical Center, Tainan, Taiwan

• Che-Han Hsu, M.D. · Cheng Ching Hospital, Taichung, Taiwan

• Joseph De Santo, M.D. · HealthCare Partners, Pasadena, USA

• Lee Rogers, M.D. · The Amputation Prevention Center at Broadlawns Medical Center, Des Moines, USA

• Kwei Quartey, M.D. · HealthCare Partners, Montebello, USA

• Lynn Tudhope, M.D. · Montana Hospital, Pretoria, South Africa

• Andre Tudhope, M.D. · Jubilee Clinical Trial Center, Hammanskraal, South Africa

• Mohammed Fulat, M.D. · Eastmed Academic Clinical Trial Center, East Lynne, South Africa

• Dirkie van Rensburg, M.D. · Park Medical Center, Witbank, South Africa

• Mashra Gani, M.D. · Mercantile Clinical Trial Center, Korsten, South Africa

• Piroon Mootsitkapun, M.D. · Faculty of Medicine, Khon Kaen University, Thailand

• Chieh-Feng Chen, M.D. · Wan Fang Hospital, Taipei, Taiwan

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2008-06-30

Primary Completion

2009-04-30

Completion

2009-06-30

Countries

• United States
• South Africa
• Taiwan
• Thailand

Study Locations